A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab plus Platinumbased Doublet Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer Subjects

Project: Research

Project Description


AcronymCANOPY-1
StatusActive
Effective start/end date20/09/1919/09/24

Keywords

  • clinical trial
  • phase 3 study
  • lung cancer
  • treatment efficacy